CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry
Authors
J Chatterjee
T Grunt
+11 more
M Hall
J Jeyaneethi
E Karteris
E Klonos
J Kumar
E Mazey
G Pados
KR Rogers‑Broadway
C Sisu
D Tsolakidis
G Wander
Publication date
31 October 2018
Publisher
'Spandidos Publications'
Abstract
© Rogers‑Broadway et al. Endometriosis is a well-known risk factor for ovarian cancer. The genetic changes that characterise endometriosis are poorly understood; however, the mechanistic target of rapamycin (mTOR) pathway is involved. In this study, we investigated the expression of key mTOR components in endometriosis and the effects of rapalogues using an endometrioid ovarian carcinoma cell line (MdAH 2774) as an in vitro model. Gene expression of mTOR, dEPTOR, Rictor and Raptor was assessed by qPcR in 24 endometriosis patients and in silico in ovarian cancer patients. Furthermore, the effects of Rapamycin, Everolimus, deforolimus, Temsirolimus, Resveratrol, and BEZ235 (dactolisib, a dual kinase inhibitor) on mTOR signalling components was assessed. mTOR showed a significant increase in the expression in endometriosis and ovarian endometrioid adenocarcinoma patients compared to non-affected controls. dEPTOR, an inhibitor of mTOR, was downregulated in the advanced stages of ovarian cancer (III and IV) compared to earlier stages (I and II). Treatment of MdAH-2774 cells with the mTOR inhibitors resulted in the significant upregulation of dEPTOR mRNA, whereas treatment with rapamycin and BEZ-235 (100 nM) resulted in downregulation of the mTOR protein expression after 48 h of treatment. None of the treat ments resulted in translocation of mTOR from cytoplasm to nucleus. Upregulation of dEPTOR is a positive prognostic marker in ovarian cancer and is increased in response to mTOR pathway inhibition suggesting that it functions as a tumour suppressor gene in endometrioid ovarian carcinoma. collectively, our data suggest the mTOR pathway as a potential connection between endometriosis and ovarian cancer and may be a potential target in the treatment of both conditions
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Sustaining member
Brunel University Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:bura.brunel.ac.uk:2438/167...
Last time updated on 18/12/2020